Does febuxostat reduce angiotensin II-induced aortic fibrosis in macrophages?
Febuxostat may reduce aortic fibrosis by inhibiting macrophage-derived TGF-β1 expression in preclinical models.
Our results suggested that FEB ameliorates Ang II-induced aortic fibrosis via suppressing macrophage-derived TGF-β1 expression.
Kondo et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: